Who Paid My Doc
Michael Warrick
Pain Medicine Sumter, SC Medical Doctor
NPI 1952472953 CMS profile 270565
129 N Washington St, Ste 320, Sumter, SC 29150
General payments
$49,896
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$4,704
Through program year 2025, Michael Warrick of Sumter, SC is reported in the CMS Open Payments database as having received $49,896 across 188 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,704 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $325 | 7 | |
| 2024 | General | $6,784 | 17 | |
| 2023 | General | $8,431 | 26 | |
| 2022 | General | $7,729 | 21 | |
| 2021 | General | $1,405 | 23 | |
| 2020 | General | $2,596 | 16 | |
| 2019 | General | $22,625 | 78 |
Beside peers
- Michael Warrick
- Pain Medicine median
- Middle half of Pain Medicine
- National median
In program year 2025, general payments to Michael Warrick were reported at $325. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.
Show as a table
| Year | Michael Warrick | Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $22,625 | $498 | $126–$1,682 | $163 |
| 2020 | $2,596 | $284 | $80–$910 | $114 |
| 2021 | $1,405 | $399 | $112–$1,219 | $132 |
| 2022 | $7,729 | $455 | $137–$1,484 | $149 |
| 2023 | $8,431 | $484 | $128–$1,495 | $160 |
| 2024 | $6,784 | $498 | $131–$1,540 | $164 |
| 2025 | $325 | $458 | $124–$1,401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 31 drugsPart D claims
2,607
Drug cost
$158,047
Branded share of claims
59.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Levorphanol Tartrate | Generic | 12 | $57,669 | |
| Xtampza Er Oxycodone Myristate | Brand | 25 | $17,209 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 754 | $16,663 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 685 | $14,985 | |
| Oxymorphone Hcl Er Oxymorphone Hcl | Brand | 24 | $11,176 | |
| Belbuca Buprenorphine Hcl | Brand | 12 | $10,258 | |
| Oxycontin Oxycodone Hcl | Brand | 12 | $9,795 | |
| Buprenorphine | Generic | 23 | $5,497 | |
| Oxycodone Hcl | Generic | 255 | $4,713 | |
| Tramadol Hcl Er Tramadol Hcl | Brand | 14 | $1,499 |
The 10 drugs with the highest cost, of 31 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 43 billing codesPaid by Medicare
$194,583
Medicare patients
510
Services billed
2,775
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Chronic kidney disease | 41% | |
| Diabetes | 38% | |
| Depression | 31% | |
| Ischemic heart disease | 29% | |
| COPD | 26% | |
| Heart failure | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
188 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pain Medicine in South Carolina
Related records
Pain Medicine in South Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in South Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.